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INTRODUCTION
Fertility potential in female patient is related to the
total number and quality of the primordial follicles
remaining in the ovary and is referred to as ovarian
reserve (OR). Ovarian reserve is a term that is used
to determine the capacity of the ovary to provide eggs
that are capable of fertilization resulting in a healthy
and successful pregnancy.1
Diminished ovarian reserve generally indicates a
poor response to any fertility treatment, and sharply
limits the possibility of successful pregnancy.2
Screening for the OR is a fundamental component
of the initial infertility evaluation, since it is a key
determinant of what treatment should be offered.3
A reduced ovarian reserve is manifested by a di-
minished ovarian response to medications for ovula-
tion induction, resulting in fewer eggs retrieved, fewer
embryos, and finally lower pregnancy rates. Many
women with unexplained infertility are suspected to
have a reduced OR when tested.3
Ideally, a test that assesses ovarian reserve should
be affordable, rapidly interpretable, and minimally in-
vasive. It also should be able to detect changes that
begin early in reproductive life. It can be performed
anytime in the menstrual cycle, and should provide
reproducible and highly accurate assessment of the
reproductive aging process.2,3
This review discusses ovarian reserve tests (ORT)
for ovulation induction and their application in deter-
mining fertility capacity for evaluating follicle pool
and for managing individualized patient ovulation in-
duction.
CLASSIFICATION OF ORT
In general, ORT are either biophysical or biochemi-
cal. (Table 1)4
This classification may be further classified as be-
ing passive or dynamic ORT, or alternatively as being
direct or in direct ORT. Passive ORT includes: age,
basal antral follicle count, basal ovarian volume, ova-
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Abstrak
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rian stromal blood flow, ovarian biopsy, basal serum
FSH, basal serum estradiol, basal serum inhibin B,
basal anti-Mullerian hormone serum. Dynamic ORT
includes: Clomiphene citrate challenge test (CCCT),
GnRH agonist stimulation test (GAST), Exogenous
FSH ovarian reserve test (EFORT). Direct ORT in-
cludes: AFC, ovarian biopsy, serum inhibin-B, and
basal serum anti-Mullerian hormone. Indirect ORT in-
cludes: basal ovarian volume, ovarian stromal blood
flow, basal serum FSH, basal serum estradiol, Clomi-
phene citrate challenge test (CCCT), GnRH agonist
stimulation test (GAST), Exogenous FSH ovarian re-
serve test (EFORT).5


















PHYSIOLOGY OF OVARIAN RESERVE
Human follicles begin their development during the
fourth month of fetal life and by the fifth month of
intrauterine life, a maximum of approximately 7 mil-
lion primordial eggs are present. At birth, 1-2 millions
eggs are present and by puberty only around 25 per-
cent eggs remain. About 400.000 of recruitable eggs
in women’s reproductive life span to lose approxima-
tely 1000 eggs each month either by atresia or entry
into the growth phase. Only about 450 eggs will pro-
gress to ovulation, which is finally followed by a de-
cline to the menopause when only approximately
1000 eggs remain at an average age of 50-51 years.
Only about 450 eggs will progress to ovulation.6,7
THE ASSESSMENT OF ORTs
OR Screening is a mechanism by which we can par-
tially predict the reproductive potential in specific as
well as oocytes potential in resulting in a healthy
pregnancy. The number of tests being used to diag-
nose or predict OR can simply be classified into two
groups: Passive testing and dynamic testing. The goal
of both approaches is to provide information regard-
ing oocytes quality and quantity.5
FEMALE AGE
Ovarian reserve declines with age, but not uniformly.
The effect of age on fertility is believed to arise from
changes in both oocyte number and quality. Most stu-
dies have found a greater frequency of cellular abnor-
malities in oocytes from older women.8-13
Female age is the better predictor of egg quality,
while basal FSH is the better predictor of egg quan-
tity.7 In women over 40 years old, current success
rates are overall low, even in women who have good
OR with more number of eggs. In this case, quantity
of eggs does not increase quality. On the contrary,
young women with limited OR can have good success
rates despite their limited cohort of eggs. Therefore,
diminished OR in young women should not be used
as an exclusion criterion for the likelihood of preg-
nancy.14
AFC
AFC is defined as the total numbers of Antral Folli-
cles Sized 2-5 or 2-10 mm being present in the ova-
ries, which is detected by USG in early follicular pha-
se.8 AFC numbers decline with age, from a range of
7-22 in early follicular phase in women aged 30 years
to 2-7 in women aged 40 years.15 In a group of nor-
mally cycling women with proven fertility, AFC also
showed a strong correlation with age, declining slow-
ly until age 37 and more rapidly there after.9,16,17
The normal AFC is 10-15 follicles over the two
ovaries, and AFC is considered abnormal when less
than 5-10. Other study suggested abnormal when AFC
< 4 for one ovary and < 8 for both ovaries.2,18,19
AFC is single best predictor of response to ovarian
stimulation, and superior to FSH.18 One study docu-
mented that women with an AFC of less than 4 were
37 times more likely to have their cycle canceled and
8.7 times more likely not to be pregnant.7
The advantages of AFC provide a direct and also
useful test to measure OR, as it has high specificity
for predicting poor response to ovarian stimulation
and failure to conceive (73-100% and 64-100% res-
pectively). However, its low sensitivity (9-73% for
poor response, and 8-33% for failure to conceive)
making AFC limit its clinical utility. In addition, this
kind of test is very much technically dependent and
tends to be a wide range of inter and intra-observer
variability.20
OVARIAN VOLUME
During a women’s life, ovarian volume changes from
0.7 cm3 at the age of 10 years to 5.8 cm3 at the age
18 years. However, at the age of 40 years, ovarian
volume tends to decrease in size, and they decrease
even further after menopause.21 These findings have
led to the evaluation of ovarian volume as a useful
marker of OR and menopausal status.22,23
Using transvaginal ultrasound, the volume of each
ovary can be calculated by measuring the length,
width, and depth with application of formula V=D1x
D2xD3. Normal measurement are generally conside-
red to be 1.5x2.0x3.5 cm. The mean ovarian volume
varied from the 18 cm3 in premenopausal women to
8 cm3 in post menopausal women, and it was sug-
gested that there was a strong association between
ovarian volume and OR.24 Ovarian volume and AFC
are good predictors of OR, and in some studies appear
better than the usual endocrine markers. Advantages
of ultrasound marker of OR over other markers in-
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clude ease of performance and incorporation into cli-
nical practice, low interobserver variability, and the
fact that the measurements remain relatively constant
from cycle to cycle.19,25 Its main limitation at present
is the lack of data regarding ovarian volume measu-
rements in the general population, both fertile and in-
fertile.4
OVARIAN STROMAL BLOOD FLOW (OSBF)
The rationale for this test is that the primordial folli-
cles in the ovary have no independent capillary net-
work, and therefore depend on their proximity to the
stromal vessels for their supply of nutrients and hor-
mones.4 By using Doppler color, ultrasound was able
to detect and measure the ovarian stromal peak sys-
tolic velocity (PSV). The ovarian stromal vascularity
and AFC were decreasing with the advancing of age.
The cut-off level for PSV was taken as 10 cm/s. When
all the other predictive factors were held constant, the
number of mature oocytes being retrieved increased
by 7% for each additional 1 cm/s increase in ovarian
PSV. A limitation of this technique is that it is very
operator dependent.
OVARIAN BIOPSY
Histological Assessment of ovarian biopsy provides a
direct assessment of follicular density. However ova-
rian biopsy is not a reliable test to assess reproductive
ageing on fertility, as there is a highly varied distri-
bution of the follicles throughout the ovary. There-
fore, the low density does not necessarily indicate a
low ovarian reserve.3,26,27
Apart from being invasive with inherent risks and
unknown future adverse effects on fertility, the main
problem with this technique is there are no standard-
ized measures for ovarian density among histopatho-
logy laboratories, and may account for the large dis-
crepancy in follicle numbers reported by various labo-
ratories.4,28
FSH SERUM
Day 3 FSH is one of the most widely used measures
of ovarian reserve and was proposed 20 years ago
with the emergence of IVF.11,29,30 The test is an in-
direct assessment of ovarian reserve which measures
pituitary production of FSH in response to ovarian
hormones.
Advancement of female age has been associated
with a slow and steady compensatory elevation in
FSH and a decrease in ovarian response.31 Persistent
elevated basal FSH levels are consistent with dimin-
ished ovarian reserve. However, some women expe-
rience transient elevated basal FSH levels unrelated
to their pool of primordial follicles.32
FSH measurements are typically combined with es-
tradiol to enhance the sensitivity of testing. If the FSH
or the estradiol level is high on day 3, patients are
more likely to respond poorly to stimulate with gona-
dotropins and have greatly reduced pregnancy rates.
This is due to the aging follicle’s failure to produce
adequate amounts of inhibin, a hormone that feeds
back to the pituitary to suppress FSH production.2,9
Basal FSH levels have been well studied, easily
obtained, reliable, and inexpensive; and have been
shown to be a superior predictor of IVF outcome
compared with age alone. Some limitations of basal
FSH levels in predicting OR include: relatively high
incidence of false-positive values in younger women,
high inter-cycle and inter-sample variability, different
threshold levels used in different studies, and overlap
between normal and abnormal levels especially in
younger women.18
The cut-off values for basal FSH vary from 10.8
to 17 IU/l. The end points included pregnancy rates,
ongoing pregnancy rates, number of oocytes or can-
cellation rates.8 In general, a level between 5 and 10
mIU/ml is considered to be normal. Levels higher
than 10 and 15 mIU/ml are considered borderline, and
≥ 16 mIU/ml are considered elevated, indicating di-
minished success with infertility treatment.19 Further-
more, another study confirmed a clear fall of preg-
nancy rate when FSH level was > 20 ml/IU.4,33
Elevated basal FSH levels are indicative of dimin-
ished ovarian reserve, and women with increased ba-
sal FSH levels frequently have decreased oocytes be-
ing retrieved in IVF program. On the contrary, of
those who achieved pregnancy, about 98% had nor-
mal findings on the OR tests.8
It appears that the highest value is of most prog-
nostic significance.14 A meta-analysis of studies on
basal FSH as a predictor of pregnancy confirmed a
wide range of sensitivities (0.03-0.85) and specifici-
ties (0.20-1.00).5,18,34
ESTRADIOL (E2)
The estradiol is elevated due to the elevation of FSH
earlier in the cycle. Estradiol levels are commonly as-
sessed during the early follicular phase of the men-
strual cycle by infertility specialists as part of the hor-
monal profiling component of the patient work-up,
because it is a simple, inexpensive, and effective
screening tool. High estrogen level on day 3 of cycle
is indicative of Diminished Ovarian Reserve (DOR)
even if the FSH level is completely normal. So it is
very important to measure both day 3 FSH and estro-
gen (E2) levels since an elevation in one or both tests
may be equally predictive of decreased egg number
and lower egg quality.35
Day 3 serum E2 levels may not be useful for ovar-
ian reserve evaluation but they may help to indicate
whether an ovulation induction should be cancelled.
Therefore, they should be included in the female
screening for infertility treatment. Normal Day 3 es-
trogen levels vary from < 50 to < 80 pg/ml.2,9 Ideally,
day 3 estrogen levels should be less than 50 pg/ml.
Day 3 estrogen levels greater than 100 pg/ml are con-
sidered abnormal.35
Those with PCOs can display a high estradiol since
many antral follicles produce a bit of estradiol.7,36
Premature elevations of estradiol in the early folli-
cular phase are driven by rising FSH levels in women
with declining ovarian reserve. Abnormally elevated
estrogen levels then send a negative feed-back on pi-
tuitary production of FSH and mask an elevation that
might otherwise reveal diminished ovarian reserve.
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INHIBIN
Inhibin is a glycoprotein hormone, which is produced
by granulosa cells of preantral and early antral folli-
cles. Inhibin levels vary during the menstrual cycle
and is a direct measure of ovarian reserve when being
assessed in the early follicular phase of the menstrual
cycle.9 During a normal menstrual cycle, Inhibin B
serum concentration increases gradually in the folli-
cular phase to reach a peak at 7 days prior to the LH
surge. It has been established that FSH secretion is
controlled by Inhibin B and thus, the serum concen-
trations of Inhibin B and FSH are inversely related,
and at low serum levels of Inhibin B, FSH concen-
tration goes up.2
Normal cut-off inhibin B levels range from ≥ 45-80
pg/ml. It has been suggested that women with low
day 3 serum concentrations of inhibin-B have less
ovarian reserve than women with high day 3 inhibin-
B. Reduced secretion of inhibin B has been reported
in women 35 years and older who have a normal men-
strual cycle and a normal day 3 FSH level, compared
with a similar group of women who were younger
than 35 years. The data suggest that the serum inhibin
B level might be an earlier predictor of loss of ovarian
reserve when compared to the serum FSH level.1,5
One group of investigators demonstrated that wo-
men with clinical evidence of diminished ovarian re-
serve but a normal FSH level also had low inhibin-B
production. The highest sensitivity (81%) and speci-
ficity (81%) were obtained at a serum level of 56
pg/ml where the end-point was the number of oocytes
collected.37
Inhibin-B testing involves a simple blood draw.
However, routine testing for serum inhibin B levels
is not recommended, due to limited availability of re-
liable assays and controversy concerning its prognos-
tic value.9
AMH
AMH is a glycoprotein growth factor and a member
of the transforming growth factor-ß superfamily. An-
tral follicles are considered to be the primary source
of circulating AMH as they contain a large number
of granulosa cells. Clinical data in IVF suggests that
AMH is preferentially and constantly secreted by
small rather than large antral follicles. Granulosa cells
secrete AMH into both the bloodstream and follicular
fluid. The number of small antral follicles is directly
related to the total size of the primordial follicle pool.
With the decrease in the number of antral follicles
with age, AMH serum levels also become diminished
and will invariably become undetectable near meno-
pause.15
Range of AMH-1 3 ng/ml is concidered to be nor-
mal, 0.3-0.9 ng/ml to be low, and less than 0.3 to be
very low. AMH levels less than 0.3 - 0.5 ng/ml are
associated with increased IVF cycle cancellation rates
and fewer eggs retrieved from the ovaries. While
AMH levels greater than 2.5 ng/ml are associated
with greater number of eggs retrieved and a better
fertility potential.38
Serum AMH levels in female are almost undetect-
able at birth, and increase slightly around the age of
3 years. AMH levels continue to increase during pu-
berty, then reach their peak after puberty and decrease
thereafter.39 A progressive decline occurs throughout
reproductive life as the follicular reserve becomes de-
pleted39,40 and finally becomes undetectable after me-
nopause.41,42
The potential advantages of AMH compared with
other conventional markers of ovarian reserve inclu-
de: it is the earliest marker to change with age; it has
the least variability from cycle to cycle; it has the
least variability when measured on different days of
the same cycle.9,19
However, utility of AMH is limited in PCOs and
obesity. In a recent series investigating AMH levels
in women with PCOs, circulating levels of AMH are
higher in women with PCOs than those without PCOs.
This finding is thought to be indicative of oligo-
ovulation and poor follicular development in polycys-
tic ovaries.9,14,41,43,44 AMH levels have been found
to be two to three times higher in PCOs women.5,18
The consistently positive correlation between AMH
and PCOs may suggest a future role for this marker
as a diagnostic tool. On the contrary, women who are
overweight have 70% lower AMH levels than thin
women, indicating that obesity may be associated
with decreased ovarian reserve and/or with ovarian
dysfunction.9
Serum AMH levels correlate strongly with the
number of antral follicles and follicle depletion. AMH
is thought to be the first ovarian reserve marker that
decline at an earlier stage compared with FSH, estra-
diol, and inhibin-B.19
The currently available literature indicates that
AMH may be a superior marker for predicting ovarian
response over either age of the patient, day 3 FSH,
estradiol or inhibin B, whereas the vast majority of
studies have found AMH and AFC to have similar
predictive value for the poor response. Furthermore,
several studies have shown that AFC and AMH mar-
kers are equivalent in terms of their high accuracy in
predicting ovarian reserve.19
CLOMPHINE CITRATE CHALLENGE TEST
(CCCT)
Provocative tests of ovarian reserve, such as CCCT,
GAST and EFORT are more sensitive indicators of
ovarian reserve than basal tests. Among those, CCCT
seems to be the best to predict ovarian reserve, and
is an indirect testing of OR.9 This test involves the
oral administration of 100 milligrams of clomiphene
citrate on menstrual cycle days 5-9. Blood levels of
FSH and estradiol are measured on cycle day 3 and
the level of FSH is also measured on cycle day 10.
The rationale behind the test is that once clomiphene
citrate is administered, FSH and LH levels rise, fol-
lowed by an increase in estradiol and inhibin. An ele-
vated FSH (≥ 10 mIU/ml) on either day 3 and 10
indicates diminished ovarian reserve. The CCCT can
help identify patients with diminished OR that was
not detected by basal FSH measurements. 
The advantages of the CCCT include: The addition
of day 10 FSH assessment improves the sensitivity of
the CCCT over basal FSH measurement; both tests
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are relatively noninvasive; and rapid measures of ova-
rian reserve. However, this test become more expen-
sive since it used two blood draws instead of one,
with a significant inter-cycle variability, and high in-
tra-cycle variability.9
The basal FSH test and CCCT have high specificity
(98% to 99% for each) as an assessment of reproduc-
tive performance in infertile women and generate few
false-positive results.12 However, the sensitivity of
the tests is low (between 7% and 8% for basal FSH
and between 25% and 40% for the CCCT). Such low
sensitivity means that many women will not conceive
after infertility treatment despite a normal test re-
sult.12,45
Theoretically the CCCT was designed to detect low
ovarian reserve that would not be discovered by a
single FSH and/or E2 measurements.2
GONADOTROPHIN AGONIST STIMU-
LATION TEST (GAST)
This test evaluates the estradiol serum concentration
change from cycle day 2 to day 3 after administration
of a GnRH agonist such as leuprolide acetate (Lup-
ron) on day 2 or 3, causing a temporary increase in
pituitary secretion of FSH and LH.4,46 A prompt es-
tradiol response to GnRH agonist may be associated
with a better ovarian reserve.8 In a significant study,
the actual increase in estradiol concentration from day
2 to day 3 following GnRH agonist administration on
day 2 was a better predictor of ovarian reserve than
age and basal FSH.4
The sensitivity of GnRH agonist testing for preg-
nancy is moderate (32% to 89%); specificity ranges
from 79% to 97%).9,20
EXOGENOUS FSH OVARIAN RESERVE
TEST (EFORT)
The exogenous FSH ovarian reserve test was designed
to screen for good or poor response in IVF. The
change of estradiol levels in response to 300 IU of
FSH administered on cycle day 3 provides the dyna-
mic component to this test and has recently been
shown to demonstrate less intercycle variability than
basal FSH levels. However, the value of this parame-
ter as an independent variable predictive of IVF out-
come has not been fully adminished, and the ability
of this test to differentiate between normal and dimi-
nished ovarian reserve appears to be limited.14
A recent randomized, prospective study in which
basal and dynamic tests of ovarian reserve were com-
pared revealed the EFORT as being the best predictor
of ovarian reserve.47
CONCLUSION
Based on the advantages and limitations including
sensitivity and specificity, inter and intra cycle vari-
ability, ease and practice and affordable of every OR
test, the most possible tests that could be performed
in clinical setting are basal FSH, basal estradiol and
basal AFC, basal AMH and CCCT.
AMH is suggested as the best OR test since it is
the earliest marker to change with age and has the
least variability from cycle to cycle, even when meas-
ured on different days of the same cycle. However,
the use of AMH is still limited in PCOs and obesity
patients.
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